Cositecan 

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameCositecan 
Drug Alias Namecositecanum考司替康可司替康BNP KarenitecinKarenitecin +[17] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDNA topoisomerase I inhibitors
TargetsDNA topoisomerase I
Therapy Area/IndicationsCNS Embryonal TumorCarcinoma, Non-Small-Cell LungLung Neoplasms +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesPolandRomania +[6] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBionumerik
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBionumerik Pharmaceuticals IncH Lee Moffitt Cancer Center & Research InstituteNational Cancer Institute
Active IndicationsN/A
Inactive IndicationsCNS Embryonal TumorCarcinoma, Non-Small-Cell LungLung Neoplasms +[9] 

Other Information

ATC CodeN/A
Related LinksKEGG